vs
Palomar Holdings, Inc.（PLMR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Palomar Holdings, Inc.的季度营收约是再鼎医药的2.0倍（$253.4M vs $127.1M），Palomar Holdings, Inc.同比增速更快（62.7% vs 17.1%），Palomar Holdings, Inc.自由现金流更多（$409.0M vs $-26.7M），过去两年Palomar Holdings, Inc.的营收复合增速更高（46.2% vs 20.8%）
Palomar Holdings, Inc.是一家专业保险控股企业，主要为存在巨灾风险敞口的住宅及商业资产提供财产保险产品，业务范围覆盖美国全境，核心业务板块包含地震、洪水、风暴等高危财产保障服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PLMR vs ZLAB — 直观对比
营收规模更大
PLMR
是对方的2.0倍
$127.1M
营收增速更快
PLMR
高出45.5%
17.1%
自由现金流更多
PLMR
多$435.7M
$-26.7M
两年增速更快
PLMR
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $253.4M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 28.7% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 62.7% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $2.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLMRZLAB
| Q4 25 | $253.4M | $127.1M | ||
| Q3 25 | $244.7M | $115.4M | ||
| Q2 25 | $203.3M | $109.1M | ||
| Q1 25 | $174.6M | $105.7M | ||
| Q4 24 | $155.8M | $108.5M | ||
| Q3 24 | $148.5M | $101.8M | ||
| Q2 24 | $131.1M | $100.1M | ||
| Q1 24 | $118.5M | $87.1M |
净利润PLMRZLAB
| Q4 25 | — | — | ||
| Q3 25 | $51.5M | $-36.0M | ||
| Q2 25 | $46.5M | $-40.7M | ||
| Q1 25 | $42.9M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $30.5M | $-41.7M | ||
| Q2 24 | $25.7M | $-80.3M | ||
| Q1 24 | $26.4M | $-53.5M |
毛利率PLMRZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率PLMRZLAB
| Q4 25 | 28.7% | -54.6% | ||
| Q3 25 | 27.4% | -42.3% | ||
| Q2 25 | 29.5% | -50.3% | ||
| Q1 25 | 30.8% | -53.3% | ||
| Q4 24 | 28.9% | -62.6% | ||
| Q3 24 | 25.9% | -66.6% | ||
| Q2 24 | 25.5% | -76.0% | ||
| Q1 24 | 29.0% | -80.7% |
净利率PLMRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 21.0% | -31.2% | ||
| Q2 25 | 22.9% | -37.3% | ||
| Q1 25 | 24.6% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 20.5% | -40.9% | ||
| Q2 24 | 19.6% | -80.2% | ||
| Q1 24 | 22.3% | -61.4% |
每股收益（稀释后）PLMRZLAB
| Q4 25 | $2.05 | $-0.05 | ||
| Q3 25 | $1.87 | $-0.03 | ||
| Q2 25 | $1.68 | $-0.04 | ||
| Q1 25 | $1.57 | $-0.04 | ||
| Q4 24 | $1.29 | $-0.09 | ||
| Q3 24 | $1.15 | $-0.04 | ||
| Q2 24 | $1.00 | $-0.08 | ||
| Q1 24 | $1.04 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $106.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $942.7M | $715.5M |
| 总资产 | $3.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLMRZLAB
| Q4 25 | $106.9M | $689.6M | ||
| Q3 25 | $111.7M | $717.2M | ||
| Q2 25 | $81.3M | $732.2M | ||
| Q1 25 | $119.3M | $757.3M | ||
| Q4 24 | $80.4M | $779.7M | ||
| Q3 24 | $86.5M | $616.1M | ||
| Q2 24 | $47.8M | $630.0M | ||
| Q1 24 | $61.4M | $650.8M |
股东权益PLMRZLAB
| Q4 25 | $942.7M | $715.5M | ||
| Q3 25 | $878.1M | $759.9M | ||
| Q2 25 | $847.2M | $791.7M | ||
| Q1 25 | $790.4M | $810.8M | ||
| Q4 24 | $729.0M | $840.9M | ||
| Q3 24 | $703.3M | $667.7M | ||
| Q2 24 | $532.6M | $704.2M | ||
| Q1 24 | $501.7M | $762.2M |
总资产PLMRZLAB
| Q4 25 | $3.1B | $1.2B | ||
| Q3 25 | $2.9B | $1.2B | ||
| Q2 25 | $2.8B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.3B | $985.3M | ||
| Q2 24 | $2.0B | $987.4M | ||
| Q1 24 | $1.9B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $409.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $409.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 161.4% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $700.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PLMRZLAB
| Q4 25 | $409.1M | $-26.0M | ||
| Q3 25 | $83.6M | $-32.0M | ||
| Q2 25 | $120.9M | $-31.0M | ||
| Q1 25 | $87.2M | $-61.7M | ||
| Q4 24 | $261.2M | $-55.8M | ||
| Q3 24 | $100.3M | $-26.8M | ||
| Q2 24 | $55.1M | $-42.2M | ||
| Q1 24 | $33.1M | $-90.1M |
自由现金流PLMRZLAB
| Q4 25 | $409.0M | $-26.7M | ||
| Q3 25 | $83.6M | $-35.0M | ||
| Q2 25 | $120.8M | $-33.9M | ||
| Q1 25 | $87.1M | $-63.2M | ||
| Q4 24 | $260.9M | $-58.4M | ||
| Q3 24 | $100.1M | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率PLMRZLAB
| Q4 25 | 161.4% | -21.0% | ||
| Q3 25 | 34.2% | -30.4% | ||
| Q2 25 | 59.4% | -31.1% | ||
| Q1 25 | 49.9% | -59.9% | ||
| Q4 24 | 167.5% | -53.8% | ||
| Q3 24 | 67.4% | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度PLMRZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率PLMRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 2.60× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.29× | — | ||
| Q2 24 | 2.14× | — | ||
| Q1 24 | 1.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLMR
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
